“Second-generation androgen receptor inhibitors in therapy of non-metastatic castration resistant prostate cancer: role of safety profile and effect on quality of life” (2022) Voprosy onkologii, 67(2), pp. 217–226. doi:10.37469/0507-3758-2021-67-2-217-226.